Risk-stratified CA125 screening integrating CA125 trajectories, trajectory-specific progression and transvaginal ultrasound for ovarian cancer

Table 1 Associations of CA125 trajectories with OC incidence and mortality

CA125 trajectories	Participants, N (%)	Events, N (%)	Follow-up, 10,000 PYs	Rates of events, per 10,000 PYs	Unadjusted HR (95%CI)	P value*	Adjusted HR (95%CI)^†	P value^†
OC incidence	28,456(100.0)	250(100.0)	20.82	12.01
CA125_SN	17,099(60.1)	101(40.4)	12.62	8.00	Ref.	< 0.001	Ref.
CA125_LP	1740(6.1)	9(3.6)	1.22	7.35	0.93(0.47–1.85)		0.92(0.46–1.81)	0.799
CA125_SP	6069(21.3)	70(28.0)	4.28	16.35	2.09(1.54–2.84)		2.00(1.47–2.73)	< 0.001
CA125_GP	3548(12.5)	70(28.0)	2.70	25.92	3.17(2.34–4.30)		3.06(2.25–4.16)	< 0.001
OC mortality	28,456(100.0)	218(100.0)	39.53	5.52
CA125_SN	17,099(60.1)	102(46.8)	24.13	4.23	Ref.	< 0.001	Ref.
CA125_LP	1740(6.1)	7(3.2)	2.41	2.91	0.69(0.32–1.48)		0.72(0.34–1.55)	0.404
CA125_SP	6069(21.3)	54(24.8)	8.14	6.63	1.58(1.13–2.19)		1.58(1.13–2.21)	0.007
CA125_GP	3548(12.5)	55(25.2)	4.84	11.36	2.69(1.94–3.74)		2.60(1.87–3.62)	< 0.001

Note: PY, person-year; IR, incidence rate; HR (95%CI), hazard ratio (95% confidential interval); *,log-rank test; †, adjusted available factors associated with CA125 trajectories as observed in Supplementary Table S1

ISSN: 1757-2215